Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Cynomolgus / Rhesus macaque CTLA-4, Avi Tag (Avitag™), 200µg  

Recombinant Biotinylated Cynomolgus / Rhesus macaque CTLA-4, Avi Tag (Avitag™), 200µg

MABSol® Biotinylated Cynomolgus / Rhesus macaque CTLA-4 Protein, Avitag™,His Tag (PD1-H82F2) is expressed from human HEK293 cells

Synonym
recombinant, cynomolgus, biotinylated, protein CTLA4, CD152, CELIAC3, GRD4, GSE, ICOS, IDDM12

More details

CT4-C82E5-200

Availability: within 7 days

1 380,00 €

Background
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4, an inhibitory receptor for B7 molecules. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.

Source
Recombinant Biotinylated Cynomolgus / Rhesus macaque CTLA-4, Avitag,His Tag (CT4-C82E5) is expressed from human 293 cells (HEK293). It contains AA Ala 37 - Ser 160 (Accession # G7PL88-1). In the region Ala 37 - Ser 160, the AA sequence of Cynomolgus and Rhesus macaque CTLA-4 are homologus.
Predicted N-terminus: Ala 37

Molecular Characterization
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 15.9 kDa. The protein migrates as 20-26 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>92% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22µm filtered solution in PBS (pH 7.4) with Trehalose as protectant.
Contact us for customized product form or formulation.

Reconstitution
Reconstitute at 200 μg/mL in sterile deionized water. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the COA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
4-8°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrosbiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.
Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays. 

References

(1) Waterhouse P, et al., 1995, Science 270 (5238): 985–8.
(2) Magistrelli G, et al., 1999. Eur. J. Immunol. 29 (11): 3596–602.
(3) Rudd, CE. et al., 2009, Immunol. Rev. 229 (1): 12-26.